Bain Capital’s buyout of Mitsubishi Tanabe Pharma brings a company with a drug ... and metabolic disease. This business is the pharmaceuticals division of Japanese conglomerate Mitsubishi ...

Bain Capital has agreed to acquire Mitsubishi Chemical Group’s4188-1.54%decrease; red down pointing triangle pharmaceutical business for ... it will buy Mitsubishi Tanabe Pharma for about ...

Mitsubishi Tanabe Pharma is being sold to Bain Capital for about $3.3 billion. Eisai expects a Leqembi "expansion phase" on the horizon. And more. 1. Astellas shifts investment focus to later ...

TOKYO, Feb 7 (Reuters) - U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth ... investment in its core chemicals business as well as to help it reduce ...

Private equity firm Bain Capital agreed to acquire Mitsubishi ... Sciences. Tanabe Pharma will continue to build on its legacy of medical innovation while boosting growth via business development ...

TOKYO & BOSTON--(BUSINESS WIRE)--Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ...

Chemical companies in the US and Europe began exiting the pharmaceutical industry in the mid-1990s, when the British firm ICI spun off its Zeneca drug business. In Japan, many major chemical ...

The Boston private equity firm said the deal followed several recent initiatives by the Japanese government and regulators to “accelerate the development and approval of innovative medicines.” ...

Bain Capital has agreed to acquire Mitsubishi Chemical Group’s pharmaceutical business for more than $ ... said Friday that it will buy Mitsubishi Tanabe Pharma for about 510 billion yen ...